The Effect of ApoE Genotype, Plasmalogen Biosynthesis, and Reverse Cholesterol Transport Biomarkers on Cognition and Odds of Alzheimer’s Disease in Elderly.

Slides:



Advertisements
Similar presentations
EPIDEMIOLOGY AND GENETICS OF ALZHEIMER´S DISEASE
Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Sue Griffin, PhD Dillard Professor and Vice Chair Donald W. Reynolds Department of Geriatrics University of Arkansas For Medical Sciences Research Director.
Department of Neurology, Mayo Clinic Arizona
Genetic Variants Associated with Late-Onset Alzheimer Disease By: Sarah Hinton, University of Georgia 2014 Pharm.D. candidate Preceptor: Dr. Ali Rahimi.
Etiopathogenesis of Alzheimer's disease
Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.
The Aging Brain The brain changes with age The frontal cortex & hippocampus are critical to learning, memory, planning and other cognitive activities,
TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE
BME 482 Kevin Sylvestre.  35 million cases of Alzheimer’s disease (AD) in U.S. alone  Causes are widely studied  Leading theory- Amyloid Cascade Hypothesis.
MECHANISMS OF AGING TheoryPrinciples DNA & Genetic Theory Aging is predetermined by genetic programming. Neuroendocrine Theory Loss of hypothalamic regulation.
Amyloid beta protein may initiate a cascade leading to AD pathology.
Lipid Metabolism 3: Cholesterol biosynthesis, lipoprotein metabolism, steroid and eicosanoid synthesis Bioc 460 Spring Lecture 37 (Miesfeld) Steroids.
Ambulatory Blood Pressure Profiles in Adolescents with Type 1 Diabetes Andrew J. Ellis 1,2, B.A.; David M. Maahs 2, M.D. Ph.D.; Franziska K. Bishop 2,
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Mild Cognitive Impairment
INTRODUCTION Mutations in Presenilin (PS) 1 and 2 cause familial Alzheimer’s Disease (AD) through undetermined mechanisms. PS’s are intramembranous aspartyl.
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Susan A. Farr, et al.
Biological Myths of Aging Memory declines drastically with age for all people. IQ declines drastically with age in all people. Learning becomes more difficult.
Diet and Alzheimer’s disease Andy Smith School of Psychology Cardiff University.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
ALZHEIMER PATHOLOGY AND NEUROPLASTICITY AD ATTACKS NEUROPLASTIC MECHANISMS NEUROPLASTICITY AS THE FOCUS OF THE ALZHEMIER ATTACK ALZHEIMER ATTACK AS A MODEL.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
VIII. NEURODEGENERATIVE DISEASES. - Are disorders characterized by the cellular degeneration of subsets of neurons that typically are related by function,
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Molecular mechanism for Alzheimer’s disease : searching for the possible therapeutic targets Sungkwon Chung Dept. of Physiology Sungkyunkwan Univ. School.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
Do you remember what you ate for dinner two days ago?
What is Alzheimer’s Disease?. Neurons and Neurotransmitters Neurons are cells inside the brains. Chemical transmitters (neurotransmitters) which transport.
Trafficking and processing of APP  and  -secretase.
Under the supervision of miklós jászberényi
Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
We Treat Alzheimers 20 years early? Can. Clinical neurologist-Reisa Sperling 1. Is a clinical neurologist, a neuroimaging researcher. 2.Is a leading force.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Genetic aspects of Alzheimer disease Karolina Pesz, Błażej Misiak, Maria M. Sasiadek Department of Genetics Wroclaw Medical University, Poland.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
Alzheimer’s Disease (AD)
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Fatty Acids and Cardiovascular Disease: Effects.
MargiAnne Isaia, MD MPH Advanced Nutrition Lipids 3.
The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.
Trends in Biomedical Science Theories of Alzheimer’s Disease.
Alzheimer’s Disease and Cholesterol
The cholesterol-ceramide connection as a possible link between
Cholesterol metabolism
Lipoproteins and Atheroscloresis
Lipoproteins and Atheroscloresis
Relationships of zinc and copper CSF levels and ApoE genotype in Alzheimer’s disease  Mirjana Babić Leko1, Jasna Jurasović2#, Matea Nikolac Perković3#,
Triglycerides (mmol/L)
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
Research Proposal By Thomas Raymond
Ying Cheng (1st-year PhD), supervised by Dr Gayle Doherty
Figure 1. Melatonin levels in CSF of control subjects (n = 82) and AD patients (n = 85). *, P< Decreased Melatonin Levels in Postmortem Cerebrospinal.
Volume 2, Issue 1, Pages (January 2016)
From the Indianapolis – Ibadan Dementia Research Project.
Disorders with Complex Genetics
Acetylation Unleashes Protein Demons of Dementia
Type 2 diabetes: Overlap of clinical conditions
Interactions between Amyloid β-barrel and anionic POPG membrane
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Courtney Lane-Donovan, Gary T. Philips, Joachim Herz  Neuron 
The Role of Apolipoprotein E in Alzheimer's Disease
Nat. Rev. Neurol. doi: /nrneurol
Neuroplasticity Failure in Alzheimer's Disease
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
Lipoproteins   Macromolecular complexes in the blood that transport lipids Apolipoproteins   Proteins on the surface of lipoproteins; they play critical.
Presentation transcript:

The Effect of ApoE Genotype, Plasmalogen Biosynthesis, and Reverse Cholesterol Transport Biomarkers on Cognition and Odds of Alzheimer’s Disease in Elderly Persons Dayan Goodenowe 1, Tara Smith 1, Vijitha Senanayake 1, Bassirou Chitou 1, Asuka Mochizuki 1, Sue E. Leurgans 2, David A. Bennett 2 1 Phenomenome Discoveries Inc., Saskatoon, Saskatchewan, Canada. 2 Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA Reduced cholesterol transport, Apolipoprotein E (ApoE) ε4 and depleted plasmalogens (PlsEtn) are hypothesized to be mechanistically involved in the etiology of dementia and AD pathology. Serum biomarkers of PlsEtn biosynthesis were measured in 862 elderly subjects and the relationships between cholesterol transport biomarkers, ApoE allele status, cognition and incident AD was determined. Plasmalogens and Cognition – Mechanism and Post-Mortem Studies Plasmalogens and AD Pathology – Mechanism and Post-Mortem Studies Plasmalogens and Cholesterol Regulation Plasmalogen Biosynthesis – Associations with Age and Cognition Plasmalogens and Cognition – Serum Studies Higher age and ApoE ε4 genotype were associated with lower cognition and higher odds of AD ApoE ε2 genotype, higher PBV, and a higher HDL-C/TC ratio were associated with higher cognition ApoE ε2 genotype and higher PBV were associated with lower odds of AD The PBV association with cognition was 2.5-times larger than the ApoE association with cognition PlsEtn-20:4 Serum PlsEtn Level CNLowModSevere -DHA-PlsEtn Cognitive Impairment Amyloid plaques are formed when APP is metabolized by β- secretase. β-secretase is located in the cholesterol-rich lipid raft region of the membrane Normal/healthy APP metabolism occurs via α- secretase. α-secretase is located in the phospholipid rich region of the membrane When membranes are enriched with DHA-plasmalogens, in vitro, α-secretase levels are increased and the formation of pathological amyloid (Aβ1-42) peptides is reduced Post-mortem human brain analyses reveal that persons with high levels of DHA-plasmalogens have low levels of Alzheimer’s pathology (Rush University, n=100, corrected for age, education, and gender) The fusion and release of neurotransmitters from presynaptic vesicles is critical for normal neuron function PlsEtn-18:1 PtdEtn-20:4 PtdEtn-18:1 In vitro studies have shown that adequate membrane levels of polyunsaturated fatty acid (PUFA) containing plasmalogens (PlsEtn) are needed for membrane fusion Post-mortem human brain analyses reveal that persons with high levels of DHA-plasmalogens have higher cognition (Rush University, n=100, corrected for age, education, and gender) Background and Introduction Serum levels of DHA-PlsEtn are decreased in cognitively impaired subjects. Subjects with severe cognitive impairment have lower levels than subjects with mild cognitive impairment (Goodenowe et al., 2007) ApoE is the predominant cholesterol transport protein in the brain. The different ApoE isoforms have significantly different cholesterol efflux activity (ε2> ε 3> ε4, Michikawa, 2000) When membranes are enriched with DHA- plasmalogens, sterol-O-acetyltransferase (SOAT) levels are increased, resulting in increased cholesterol esterification and increased cholesterol efflux, which results in decreased cellular cholesterol levels (Mankidy et al., 2011) -ε2-ε2 -ε3-ε3 -ε4-ε4 Overall plasmalogen biosynthesis is stable from age and then decreases; Plasmalogen Biosynthesis is decreased in subjects with cognitive impairment; Subjects with severe cognitive impairment have lower PBV than subjects with mild cognitive impairment (Goodenowe et al, 2015) Serum PBV An overall Plasmalogen Biosynthesis Value (PBV) can be generated by determining the ratio of key plasmalogen precursors and products (Goodenowe et al., 2015) Plasmalogens are synthetized in peroxisomes by specialized enzymes Average age: 71+/-9 Clinical VariablesOutcome Analysis: Cognition and AD Outcome Analysis: Contribution of Variables Results – ApoE, RCT, PBV, and AD ApoE - PBV Interaction Analyses Conclusions Low PBV is the largest contributor (other than age) to reduced cognition in the elderly with an overall effect size 2.5-times larger than ApoE genotype; High PBV or ApoE ε2 genotype is associated with increased RCT (HDL-C/TC ratio); High PBV neutralizes the increased probability of AD associated with the ApoE ε4 genotype independent of its effect on RCT. ε4ε4 ε3ε3 ε2ε2 ε4ε4 ε3ε3 ε2ε2 Probability of AD Global Cognition HDL-C / Total Cholesterol PBV significantly affected the probability of AD in ApoE e3 and e4 carriers; PBV significantly affected the cognition level in ApoE e2, e3 and e4 carriers; Both ApoE and PBV were associated with HDL-C/TC ratio; PBV affected the HDL-C/TC ratio in e2 and e3 carriers but not e4 carriers; The PBV effect on HDL-C/TC is not a viable mechanism to explain the PBV effect on e4 carriers. ApoE and Cholesterol Regulation